Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

Vaccine

Volumn 32, Issue 46, 2014, Pages 6146-6156

  Nolan, Terry ^a   Bravo, Lulu ^b   Ceballos, Ana ^c   Mitha, Essack ^d   Gray, Glenda ^e   Quiambao, Beatriz ^f   Patel, Sanjay S ^g   Bizjajeva, Svetlana ^g   Bock, Hans ^g   Nazaire Bermal, Nancy ^g   Forleo Neto, Eduardo ^g   Cioppa, Giovanni Della ^g   Narasimhan, Vas ^g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c Instituto Médico Rio Cuarto   (Argentina)

^d Newtown Clinical Research Centre   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^g Novartis Vaccines and Diagnostics Inc ^*  (United States)

Author keywords

Adjuvant; Children; Fluad ; Influenza vaccine; MF59

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA, HUMAN; MULTICENTER STUDY; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SINGLE-BLIND METHOD; SQUALENE; VACCINES, SUBUNIT;

EID: 84907973731     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.068     Document Type: Article

References (40)

1. Ghendon Y.Z., Kaira A.N., Elshina G.A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 2006, 134(1):71-78.
2. Izurieta H.S., Thompson W.W., Kramarz P., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232-239.
3. Neuzil K.M., Mellen B.G., Wright P.F., et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
4. Principi N., Esposito S., Marchisio P., et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003, 22(Suppl. 10):S207-S210.
5. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
6. Nair H., Brooks W.A., Katz M., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930.
7. CDC Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010, 59:1-62.
8. CDC National early season flu vaccination coverage, United States 2012-2013 Flu season 2013, CDC, http://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2012.htm#ref1 (accessed August 21, 2013).
9. Jefferson T., Rivetti A., Harnden A., et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, 2(2). (CD004879).
10. Humiston S.G., Szilagyi P.G., Iwane M.K., et al. The feasibility of universal influenza vaccination for infants and toddlers. Arch Pediatr Adolesc Med 2004, 158:867-874.
11. Zambon M.C. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999, 44:3-9.
12. Treanor J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 2004, 350:218-220.
13. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
14. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine 2009, 27:D65-D68.
15. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59C.1-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
16. Khurana S., Verma N., Yewdell J.W., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccine. Sci Transl Med 2011, 85:85r48.
17. Khurana S., Chearwae W., Castellino F., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra5.
18. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6(5):699-710.
19. O'Hagan D.T., Ott G.S., De Gregorio E., et al. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30(29):4341-4348.
20. Pellegrini M., Nicolay U., Lindert K., et al. MF59-adjuvanted versus non-adjuvanted vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
21. Banzhoff A., Haertel S., Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccine 2011, 7(5):539-548.
22. ®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43(9):702-706.
23. Vesikari T., Knuf M., Wutzler P., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
24. Stephenson I., Nicholson K.G., Gluck R., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
25. WHO Annual consultation on the composition of influenza vaccine for the Southern Hemisphere 26th-30th September 2011 2013, WHO, Available at: http://www.nimr.mrc.ac.uk/documents/about/interim-report-sep-2011.pdf (accessed October 25, 2013).
26. Black S., Nicolay U., Vesikari T., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30:1081-1085.
27. Ansaldi F., Zancolli M., Durando P., et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010, 28:4123-4129.
28. Baldo V., Baldovin T., Pellegrini M., et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010, 2010:517198.
29. Vesikari T., Pellegrini M., Karvonen A., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
30. ®-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 2011, 29(47):8696-8704.
31. Hobson D., Curry R.L., Beare A.S., et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J Hyg (Lond) 1972, 70:767-777.
32. Coudeville L., Ballieux F., Riche B., et al. Relationship between haemagglutinin-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random effects model. BMC Med Res Methodol 2010, 10:18.
33. Jackson L.A., Neuzil K.M., Baggs J., et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics 2006, 118(5):2032-2037.
34. Mullooly J.P., Barker W.H. Impact of type A influenza on children-a retrospective study. Am J Epidemiol 1982, 115:479-480.
35. Ampofo K., Gesteland P.H., Bender J., et al. Epidemiology, complications and cost of hospitalization in children with laboratory-confirmed influenza. Pediatrics 2006, 118:2409-2417.
36. Ansaldi F., Canepa P., Parodi V., et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009, 27:3345-3348.
37. Hay A.J., Gregory V., Douglas A.R., et al. The evolution of human influenza viruses. Philos Trans R Soc, B 2001, 356:1861-1870.
38. Ahmed S.S., Schur P.H., Macdonald N.E., et al. Narcolepsy, 2009 A(H1N1) pandemic infleunza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014, 50:1-11.
39. ®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43(9):702-706.
40. ®-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update. Scand J Infect Dis 2011, 43(11-12):993.